Inizio

Inizio is one of the world’s largest life sciences commercialization partners. Formed in 2022 by merging Ashfield and Huntsworth, it offers strategic consulting and operational support throughout the entire asset lifecycle—from clinical development to post-launch—for pharmaceutical and biotech companies. It employs over 10,000 experts across more than 50 countries—including over 750 PhDs—and serves all top global pharma companies. Its business units provide specialized support in advisory consulting, medical affairs, marketing communications, engagement solutions for HCPs/patients/payers, and biotech-specific services. The company does not develop its own drugs or maintain an internal R&D pipeline but instead enables client success through data-driven insights and omnichannel strategies.